The pharmacokinetics of xamoterol in liver disease

British Journal of Clinical Pharmacology
D P NichollsR G Shanks


The pharmacokinetics of xamoterol, a beta 1-adrenoceptor partial agonist, have been studied in patients with liver disease and a group of age- and sex-matched normal controls. No significant differences were observed after the oral administration of xamoterol 200 mg. The low bioavailability of xamoterol was confirmed (6.1% in patients, 6.9% in controls). After i.v. xamoterol 0.2 mg kg-1, no significant differences between the groups were observed. A small increase in the terminal plasma elimination half-life (t1/2) was observed in patients when compared with controls (15.3 +/- 6.4 vs 8.4 +/- 2.8 h, mean +/- s.d., P = 0.08). Renal clearance accounted for about 50% of total clearance in patients and about 30% in controls. It is suggested that in patients with heart failure, hepatic dysfunction would probably not influence xamoterol disposition.


Mar 1, 1986·British Journal of Clinical Pharmacology·T HashimotoK Kondo
Feb 1, 1988·British Journal of Clinical Pharmacology·A K ScottW Bastain
Jan 1, 1988·European Journal of Clinical Pharmacology·W BastainH F Marlow
Oct 1, 1982·British Journal of Pharmacology·A Nuttall, H M Snow
May 1, 1984·Clinical Pharmacology and Therapeutics·G JenningsR Restall
May 1, 1983·Journal of Pharmacological Methods·A Johnston, R C Woollard

❮ Previous
Next ❯


❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.